1. Pink Sheet

UK's Clinical Trials Diversity Draft Gets Over 200 Stakeholder Responses

 
• By Vibha Sharma

As the consultation period draws to a close for the UK’s new inclusion and diversity guidance, researchers and sponsors are being invited to participate in a pilot next year to submit a diversity plan as part of their clinical trial application.

colorful paper with question mark in a plastic jar on wooden table. questions and diversity concept. FAQ and Q&A background concep
The UK’s Inclusion & Diversity Plan outlines questions for trial sponsors to consider (Shutterstock)

The UK’s draft guidance on how study sponsors should go about preparing an inclusion and diversity plan as part of their clinical trial application for the research ethics committees (RECs) has already drawn over 200 comments from stakeholders.

The draft guideline was issued for an informal consultation in October and remains open for feedback until 9 December. The stakeholder responses will “help make sure the final guidance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.